Increlex for growth failure in children

24 October 2007

Ipsen has launched Increlex (mecasermin) for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor-1 (IGF-1) deficiency.

PHARMACOLOGY
Mecasermin is a human IGF-1 produced by recombinant DNA technology.

IGF–1 is the principal hormonal mediator of growth. In target tissues, IGF–1 activates the IGF–1 receptor, leading to intracellular signalling to induce and support statural growth. IGF–1 induces the uptake of glucose, fatty acids and amino acids so that metabolism supports growing tissues.

Further information: Ipsen 01753 627777

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

The most up-to-date drug information at your fingertips.

  • Get the prescribing support you need.
  • Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Register Now
Already Registered?

Forgotten password?

More from MIMS

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

An empty tablet blister pack.

Ezetimibe supply update

Availability issues have been reported for the lipid-lowering...

Woman holding blister strip of contraceptive pills

Pharmacists across England to initiate oral contraceptives

Pharmacy Contraception Service (PCS) could allow almost...